Cost effectiveness of pembrolizumab for unresectable metastatic melanoma after progression with ipilimumab in England.

Publication Type:
Poster


Citation:

Marriott E-R, Praet C, Aguiar-Ibanez R, Pellissier J, Xu R and Wang J. Cost effectiveness of pembrolizumab for unresectable metastatic melanoma after progression with ipilimumab in England. 18th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Milan, Italy. 7-11 November 2015. Poster PCN134.

 


Link to publication ⟶

⟵ Back to Search Results